key: cord-0758139-uviprgsh
authors: Ebina‐Shibuya, Risa; Horita, Nobuyuki; Namkoong, Ho; Kaneko, Takeshi
title: National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID‐19
date: 2020-06-18
journal: Respirology
DOI: 10.1111/resp.13885
sha: b9aba0452d72a6b583f6eebf2042fb322cc68059
doc_id: 758139
cord_uid: uviprgsh

See related Reply

We read the Letter from China by Guan and Zhong regarding coronavirus disease 2019 (COVID-19) with immense interest, as it provided novel insight into this catastrophic pandemic. 1 COVID-19 hotspots until February 2020 were East-Asian cities including Wuhan (China) and Yokohama (Japan) where the cruise ship Diamond Princess harboured. The mortality rate in Asia-Pacific countries increased at a slower rate until mid-April compared to some Euro-American countries. 2 Notably, COVID-19 high-burden countries in Western Europe and North America, such as Italy, Belgium, the Netherlands, the United States, Spain, France, the United Kingdom and Switzerland, do not currently recommend universal Bacillus Calmette-Guérin (BCG) vaccination because tuberculosis is not highly prevalent. 3 BCG induces trained immunity (innate immune memory) by non-specific cross-protection against non-tuberculous pathogens. 4 Therefore, some researchers believe that people vaccinated with BCG have some immune protection to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nevertheless, other researchers counter that this association can be explained by confounding factors including the abundant medical resources of the COVID-19 high-burden countries. To reduce this confounding effect, we compared population-based mortality from COVID-19 using data of only World Bank-defined highincome countries. 2, 5 The high-income countries and regions were classified into two groups based on national policies regarding universal BCG vaccination 3 : 'Currently Recommended Countries (CRC)' and 'Currently Not Recommended Countries (CNRC)'. CNRC were further divided into 'Never Recommended Countries' and 'Previously Recommended Countries' 3 ( Fig. 1) .

We analysed mortality data from 27 CRC and 23 CNRC. All CRC provide the first BCG shot at birth except for Greece (6 years), Malta (school age) and Barbados (5-6 years). Median mortality per one million population for CRC was significantly lower than that for CNRC (2.1 (interquartile range (IQR): 0.7-8.0) vs 42.6 (IQR: 13.1-139.3), Mann-Whitney P < 0.001; Fig. 1 ). Mortality rates significantly differed between the three groups (Kruskal-Wallis P < 0.001; Fig. 1 ). The highest median mortality of 146.5 (IQR: 56.6-260.5) was found in the Never Recommended Countries, followed by 34.0 (IQR: 11.0-108.4) in the Previously Recommended Countries and 2.1 (IQR: 0.7-8.0) in the CRC.

Guan and Zhong called for active prevention measures to combat the current global pandemic. 1 National policies for paediatric universal BCG vaccination possibly contribute to reducing COVID-19-related mortality. We expect that ongoing randomized trials will confirm the role of BCG vaccination in preventing COVID-19related death.

Risa Ebina-Shibuya MD, PhD, 1 Nobuyuki Horita MD, PhD, 2 Ho Namkoong MD, PhD, 3 -19) . Since the development of a diseasespecific vaccine would not be feasible within 12-18 months, proactive vaccination with an existing vaccine represents an appealing approach for boosting herd immunity against the lethal diseases such as Covid-19. The key concept is to apply existing vaccines to train the immune system. Importantly, there appeared to be a gradient of the mortality rate in the never recommended countries (median: 146.5), previously recommended countries (median: 34.0) and currently recommended countries (median: 2.1). 1 In echo to these encouraging findings, we have reviewed the existing evidence pertaining to the association between Bacillus Calmette-Guerin (BCG) vaccination and the incidence and clinical outcomes of Covid-19. Overall, most findings seemed to be in favour of the protective effects of BCG vaccination. In an observational study, Ozdemir et al. documented a lower incidence of laboratory-confirmed cases and mortality in BCG-vaccinated countries than in BCG non-vaccinated countries. 2 Another observational study reported a lower number of laboratory-confirmed cases in Asian and African countries. 3 The mortality of patients with Covid-19 was also markedly higher in countries without extensive or selective BCG vaccination. 4 However, a population-based study of 72 060 test results did not identify significant differences in the positive rate for viral assay findings between BCGvaccinated individuals and BCG non-vaccinated individuals. 5 Because of the limitations of study design and the short-lived protective effects of BCG vaccination, none of the existing studies could definitively rule in or rule out the casual association between BCG vaccination and the clinical outcomes of Covid-19. There might have been selection bias in the study participants because symptomatic individuals were more likely to undergo screening tests. 5 Moreover, there might be substantial differences in the compositions in the BCG vaccines that made the interpretation of the casual effects not straightforward. 4 Collectively, the existing evidence does not preclude the protective effects of BCG vaccination in reducing the incidence rate and mortality rate of Covid-19, which should be addressed by well-designed cohort studies from a population basis. These findings will in turn help inform policy makers whether it would be cost-effective to implement population-based vaccination to set up herd immunity against severe acute respiratory diseases such as Covid-19.

Letter from China

Worldmeter COVID-19 coronavirus pandemic

The BCG Atlas Team. The BCG World Atlas

Trained immunity: a program of innate immune memory in health and disease

World Bank Country and Lending Groups

National policies for pediatric universal BCG vaccination were associated with decreased mortality due to COVID-19

Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?

Is BCG vaccination affecting the spread and severity of COVID-19? Allergy

Is BCG vaccination causally related to reduced COVID-19 mortality?

SARS-CoV-2 rates in BCGvaccinated and unvaccinated young adults